FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

By afschroeder • February 26, 2026

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell C, Platt A, Belvisi MG, Pandya H. FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Res. 2026 Feb 23;12(1):00183-2025. doi: 10.1183/23120541.00183-2025. PMID: 41736737; PMCID: PMC12926823.

Tags: Allergy & Immunology, General Internal Medicine, Publications

Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers

Riemann S, Meulmeester FL, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Corren J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud[...]

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Chen HC, Bang MF, Wang HH, Shpargel KB, Kohn LA, Sailer D, Zhang S, McCarthy EC, Seyedsadr M, Stevens S, Pham CLH, Zhou Z, Yin[...]

The Possible Unveiling of Myasthenia Gravis via Allergy Shots

Thakor Philipp A, Anderson L. The Possible Unveiling of Myasthenia Gravis via Allergy Shots. Cureus. 2025 Sep 9;17(9):e91927. doi: 10.7759/cureus.91927. PMID: 41080268; PMCID: PMC12510673.